UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000004491
Receipt number R000005313
Scientific Title Comparison of monotherapy with irbesartan and telmisartan for treatment of essential hypertensive patients - interventional, parallel group study using home Blood Pressure monitoring -
Date of disclosure of the study information 2010/11/15
Last modified on 2011/06/23 09:20:29

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Comparison of monotherapy with irbesartan and telmisartan for treatment of essential hypertensive patients - interventional, parallel group study using home Blood Pressure monitoring -

Acronym

Comparison of monotherapy with irbesartan and telmisartan for treatment of essential hypertensive patients

Scientific Title

Comparison of monotherapy with irbesartan and telmisartan for treatment of essential hypertensive patients - interventional, parallel group study using home Blood Pressure monitoring -

Scientific Title:Acronym

Comparison of monotherapy with irbesartan and telmisartan for treatment of essential hypertensive patients

Region

Japan


Condition

Condition

Essential hypertension

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To compare the effects of monotherapies with irbesartan and telmisartan on home blood pressure, percents of achieving blood pressure targets, lipid and glucose profile

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

To compare the changes from baseline in home Systolic Blood Pressure between 12 week treatments of irbesartan and telmisartan

Key secondary outcomes

1.To compare the percents of achieving blood pressure targets in home Blood Pressure monitoring between 12 week treatments of irbesartan and telmisartan
2.To compare the changes from baseline in office blood pressure, home diastolic Blood Pressure, heart rates between 12 week treatments of irbesartan and telmisartan
3.To compare the changes from baseline in LDL-C, HDL-C, TG, FFA, FBS, HbA1C, UACR between 12 week treatments of irbesartan and telmisartan
4.To compare the changes from baseline in blood and urine examinations between 12 week treatments of irbesartan and telmisartan


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Treatment of irbesartan 50-200mg/day

Interventions/Control_2

Treatment of telmisartan 20-80mg/day

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

30 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Essential hypertensive outpatients who are without antihypertensive drug at least 4 weeks prior to randomization or without a historiy of anti-hypertensive drug
2) Office SBP >=140mmHg or DBP >=90
3) Age >=30 years
4) Subjects who gave written informed consent

Key exclusion criteria

1) Allergy against irbesartan/telmisartan
2) History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments
3) Impaired renal function (Cre>=2.0mg/dL)
4) Biliary obstructive disorders or level of alanine aminotransferase >= 100IU
5) Symptomatic (NYHA II, III or IV) congestive heart failure
6) Poor-controlled hypertension (SBP>=180, or DBP>=110 mmHg in office BP)
7) Severe arrythmia
8) Diabetes treated with thiazolidine
9) Malignancies or other diseases with poor prognosis
10) Pregnant
11) Subjects whose doctor in charge do not agree to join the trial

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hitoshi Ishihara

Organization

Ishihara medical clinic

Division name

Head

Zip code


Address

Kamodacho-aza-minamikomba 79-1, Okazaki-City, Aichi, 444-2121 Japan

TEL

0564-22-2167

Email



Public contact

Name of contact person

1st name
Middle name
Last name Hitoshi Ishihara

Organization

Nishi-Mikawa SG-ARB association

Division name

Ishihara medical clinic

Zip code


Address


TEL

0564-22-2167

Homepage URL


Email



Sponsor or person

Institute

Nishi-Mikawa SG-ARB association

Institute

Department

Personal name



Funding Source

Organization

Ishihara medical Clinic

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

石原クリニック(愛知県),トヨタ記念病院循環器科(愛知県)


Other administrative information

Date of disclosure of the study information

2010 Year 11 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2010 Year 09 Month 14 Day

Date of IRB


Anticipated trial start date

2010 Year 11 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2010 Year 11 Month 01 Day

Last modified on

2011 Year 06 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005313


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name